
Trump is privately mulling how to declare pot a less dangerous drug
Drugs in society
PACsFacebookTweetLink
Follow
Over a recent dinner at his private Bedminster, New Jersey, club, as President Donald Trump recounted his move against the country's top economic statistician and riffed on New York City politics, the conversation turned to a politically potent issue still in flux: loosening federal restrictions on marijuana.
'We need to look at that,' Trump acknowledged to the small gathering of donors, according to two people in attendance. 'That's something we're going to look at.'
Nearly a year ago, Trump suggested his return to the White House would usher in a new era for marijuana, one that would make it easier for adults to access safe products and give states greater leeway to pursue legalization. He signaled support for removing marijuana from the same legal category as dangerous narcotics like heroin. The pronouncement set him apart from many of his Republican predecessors and came as Trump courted younger Americans, minority groups and libertarian-leaning voters.
But seven months into his second term, Trump's inaction so far on marijuana remains a notable unkept commitment by a president who has acted swiftly on other campaign pledges.
Behind the scenes, the issue has exposed sharp fault lines within Trump's team. Trump's top political advisers, who have led an aggressive push to check off campaign promises, have urged action, according to two people familiar with the internal discussions. They have argued that such a move could help bolster Republican support ahead of the midterm elections.
Other policy advisers, though, remain wary, cautioning that the moral and legal ramifications of loosening marijuana restrictions could outweigh the potential gains and even backfire politically .
In a statement to CNN, White House spokeswoman Abigail Jackson said that when it comes to marijuana, 'all policy and legal requirements and implications are being considered.'
'The only interest guiding the president's policy decision is what is in the best interest of the American people,' she said.
Intensifying deliberations are happening as mixed signals are being telegraphed publicly on what Trump might do next.
Scotts Miracle-Gro CEO James Hagedorn told Fox Business last week that Trump has privately assured him and others 'multiple times' that he plans to reclassify marijuana to a less controlled category of substances. The 157-year-old lawn and garden giant has become a leader in the nascent cannabis industry, with a fast-growing hydroponics business that Federal Election Commission records show donated $500,000 to a Trump-aligned super PAC last year.
But reforming marijuana policy was noticeably absent from the top objectives recently published by Trump's newly installed head of the Drug Enforcement Administration, Terrance Cole.
Hagedorn said Cole's recent cannabis snub wasn't surprising coming from a 'career law enforcement guy.'
'I think what (Cole) needs to hear is a call from the president or the chief of staff saying, 'This is a promise he made during the campaign, and promises made are promises kept, '' he told Fox Business.
That 'promise' from Trump, as Hagedorn cast it, arrived in a social media message last year during the closing months of his presidential campaign, when he was aggressively pushing to expand his coalition beyond traditional GOP voters.
Writing on Truth Social in September, Trump announced he intended to vote for a ballot measure to legalize recreational marijuana in his home state of Florida. Trump then added that, as president, he would 'continue to focus on research to unlock the medical uses of marijuana to a Schedule 3 drug.'
Marijuana is currently classified as a Schedule 1 drug – the federal category for illicit substances with 'no currently accepted medical use and a high potential for abuse.' Moving it to Schedule 3, which the DEA defines as 'drugs with a moderate to low potential for physical and psychological dependence,' is something Trump has said he supports.
'As I have previously stated, I believe it is time to end needless arrests and incarcerations of adults for small amounts of marijuana for personal use,' Trump also wrote in the post.
He even discussed the topic with Joseph Edgar Foreman, the pro-pot rapper better known as Afroman, when the two both appeared last summer at the Libertarian Party Convention in Washington, DC.
For a time, it seemed change could come before the 2024 election.
In 2022, President Joe Biden ordered the departments of Justice and Health and Human Services to review whether marijuana should be reclassified. The next year, HHS recommended moving marijuana to Schedule 3 and in 2024 the Department of Justice initiated a new rule to codify the proposal. Biden called the move 'monumental' and a 'major step.'
But momentum stalled and Biden left office before the rule could be finalized. A hearing the DEA scheduled for the day after Trump took office was canceled and hasn't been rescheduled.
In her statement, Jackson, the White House spokeswoman, noted that the current administration is still contending with the process initiated under Biden. One White House official suggested that executive action is unlikely until that is settled. The DEA did not respond to questions from CNN.
Trump's remarks at the recent Bedminster donor dinner underscore the expectation that the president, not anyone else, will ultimately decide whether to overhaul decades of marijuana policy in the United States.
Privately, the White House has spent months researching whether and how to move ahead. Chief of Staff Susie Wiles requested affected agencies to weigh in and their responses, compiled by Trump's Domestic Policy Council, now sit in a report on her desk, two people with knowledge of the report told CNN.
One issue raised in ongoing deliberations is whether reclassifying marijuana would undermine law enforcement's ability to use the smell of marijuana as probable cause for stops and searches, one of the people said. For Trump, whose tough-on-crime platform has emphasized empowering police to pursue drug offenders, that concern could emerge as a flashpoint.
Then there's Trump's personal views. While Trump's public posture on marijuana use has softened in recent years, he remains a known teetotaler whose opinions on drug use were dramatically shaped by his late brother's alcohol addiction.
In remarks captured on video in 2018, Trump shared other – unproven – concerns about the drug.
'In Colorado, they have more accidents,' Trump said in the video. 'It does cause an I.Q. problem.'
Proponents of a change have been publicly and privately urging Trump to commit to rescheduling marijuana, arguing it would open research opportunities, create jobs and give clarity to millions of patients in states that have legalized medicinal marijuana, including many veterans.
In April, CNN reported that a group backed by the cannabis industry, American Rights and Reform PAC, aired pro-marijuana ads specifically targeting Trump's TVs at the White House and Mar-a-Lago. The PAC also donated $1 million in March to MAGA, Inc., a Trump aligned super PAC, recent FEC records show. In 2024, the marijuana company Trulieve and the US Cannabis Council contributed a combined $1 million to Trump's inauguration.
Other influential voices have urged action as well. Podcaster Joe Rogan, a key supporter during the presidential campaign, reiterated his call to legalize marijuana on his show last month. And Alex Bruesewitz, the Gen Z Trump adviser who spearheaded the Republican's courtship of young men last year, has also taken to social media lately to urge for a policy change on marijuana, suggesting it has widespread support. He called rescheduling marijuana a 'no brainer.'
Nearly 60% of Americans support legalization of recreational marijuana against just 11% of people who think it shouldn't be legal for any purpose, according to a 2024 Pew Research Center survey.
Recent polls suggest the president is at risk of losing support among young men as Rogan and other 'manosphere' influencers grow disenchanted by Trump's return to Washington. A high-profile change in marijuana policy could provide an avenue to win them back.
In a memo reported by CNN earlier this year, top Trump pollster Tony Fabrizio and his partners wrote that changing marijuana policy was 'an easy way to attract the voters needed to win in 2026, particularly young voters.'
Alayna Treene contributed to this report.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


CNN
15 minutes ago
- CNN
Live updates: Trump to meet Zelensky and EU leaders ahead of Putin summit
Update: Date: 11 min ago Title: Zelensky to arrive in Berlin for European talks with Trump Content: President Volodymyr Zelensky will arrive in Berlin today, according Ukrainian state media outlet Ukrinform, where he will join a virtual call between US President Donald Trump and European leaders. The video conference comes two days before Trump will meet Russian President Vladimir Putin in Alaska to discuss an end to the Kremlin's war in Ukraine. Putin is expected to use the meeting at Joint Base Elmendorf-Richardson, on the northern edge of Alaskan capital Anchorage, to demand Ukraine cedes territory in return for a ceasefire. Zelensky has rejected the possibility of ceding land to Russia. He will join German Chancellor Friederich Merz for a bilateral meeting while in Berlin. Update: Date: 19 min ago Title: Trump will participate in Ukraine talks today Content: President Donald Trump is participating in online talks on Ukraine today, a White House official told CNN. The talks come ahead of Trump's meeting with Russian President Vladimir Putin in Alaska on Friday. German Chancellor Friedrich Merz said yesterday he was planning to host a virtual meeting with Trump, Ukrainian President Volodymyr Zelensky and European leaders to discuss the war in Ukraine. With the Trump-Putin summit looking set to sideline Ukraine and Europe, the German government on Monday said it was arranging a meeting of its own to prepare for 'possible peace negotiations' and potential 'territorial claims.' 'The talks will focus on further options for action to put pressure on Russia,' the German government said. Merz invited the leaders of France, the United Kingdom, Finland, Italy, Poland and Ukraine to the meeting, the government said, as well as European Commission President Ursula von der Leyen, NATO Secretary General Mark Rutte, and Trump and his Vice President JD Vance.


Bloomberg
15 minutes ago
- Bloomberg
Putin Heads to Trump Summit Confident He Is Winning in Ukraine
Vladimir Putin is heading to Friday's planned summit with Donald Trump confident that Russia is in a dominant position on the battlefield as his military advances in Ukraine. That's likely to strengthen his determination to secure major territorial concessions when the Russian and US presidents meet in Alaska in return for a ceasefire that Putin has so far been reluctant to concede to Trump.


Fox News
16 minutes ago
- Fox News
More than 20 GOP attorneys general call on RFK Jr, FDA to reinstate safeguards for abortion drugs
Print Close By Landon Mion Published August 13, 2025 EXCLUSIVE: More than 20 Republican attorneys general are demanding that the Trump administration reinstate safety protocols for the abortion drug mifepristone, saying it poses "serious risks to women." In a letter obtained by Fox News Digital, 22 attorneys general called on Health and Human Services Secretary Robert F. Kennedy Jr. and Food and Drugs Administration head Martin Makary to bring back safeguards for the pills that were scrapped by the Obama and Biden administrations. "Recent comprehensive studies of the real-world effects of the chemical abortion drug mifepristone report that serious adverse events occur 22 times more often than stated on the drug's label, while the drug is less than half as effective as claimed. These facts directly contradict the drug's primary marketing message of 'safe' and 'effective,'" the letter reads, citing studies published earlier this year by the Ethics and Public Policy Center (EPPA), a Washington, D.C.-based advocacy group. The EPPA report claims the pill presents harm to women, causing 1 in 10 patients to experience a "serious adverse event," including hemorrhage, emergency room visits and ectopic pregnancy. FDA CHIEF HAS 'NO PLANS' FOR ABORTION PILL POLICY CHANGES BUT CONTINUES SAFETY REVIEW The letter, led by Kansas Attorney General Kris Kobach, comes after Kennedy Jr. asked Makary to review the latest data on mifepristone and its safety. "Based on that review, the FDA should consider reinstating safety protocols that it identified as necessary as recently as 2011 in its issuance of a Risk Evaluation and Mitigation Strategy (REMS) for mifepristone, but which were removed by the Obama and Biden administrations," the letter reads, adding that the drug should be taken off the market if safeguards cannot be put in place. "Alternatively, in light of the serious risks to women who are presently being prescribed this drug without crucial safeguards, and in the event the FDA is unable to reinstate the 2011 safety protocols for mifepristone, the FDA should consider withdrawing mifepristone from the market until it completes its review and can decide on a course of action based on objective safety and efficacy criteria," the attorneys general wrote. Sen. Josh Hawley, R-Mo., also sent a letter to Kennedy Jr. last month urging him to take immediate action to reinstate safety guardrails on mifepristone following the secretary's commitment to conducting a safety review of the drug. Makary had previously said that he had no plans to modify policies surrounding mifepristone but that the FDA would act if the data suggested there was a safety issue. Mifepristone, which is taken with another drug called misoprostol to end an early pregnancy, was first approved by the FDA in 2000 after "a thorough and comprehensive review" found it was safe and effective, according to the agency's website, which noted that periodic reviews since its approval have not identified new safety concerns. Last year, the Supreme Court rejected a challenge targeting the drug's availability. The plaintiffs had sought to restrict access to mifepristone across the country, including in Democrat-led states where abortion remains legal. The court did not rule on whether the FDA acted lawfully when it moved during the Obama and Biden administrations to ease the rules for mifepristone's use that had been established during the Clinton administration. Medication abortions made up more than half of all abortions in the U.S. health care system in 2023, according to a study by the Guttmacher Institute. MEDICAL GROUPS URGE FDA, KENNEDY TO REEXAMINE BROAD APPROVAL OF ABORTION DRUGS CLICK HERE TO GET THE FOX NEWS APP "Currently, a woman can obtain a mifepristone abortion by participating in only one telehealth visit with any approved healthcare provider (not necessarily a physician), ordering the drugs through a mail-order pharmacy, and self-administering them," the attorneys general wrote. "And the prescriber is only required to report an adverse event if he or she becomes aware that the patient has died." "The FDA's removal of these crucial safety protocols in 2016 (and in 2023) that only five years before the FDA considered necessary begs the question of whether the removal was motivated by considerations other than the safety of patients … The current FDA's dedication to the health and wellbeing of all Americans is encouraging, as is the much-needed review of mifepristone that Secretary Kennedy has promised," the letter concludes. Print Close URL